Back to top
more

McKesson (MCK)

(Delayed Data from NYSE)

$589.95 USD

589.95
728,168

-1.12 (-0.19%)

Updated Jun 14, 2024 04:00 PM ET

After-Market: $590.00 +0.05 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 29% (178 out of 250)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Will Core Distribution Unit Aid McKesson (MCK) Q1 Earnings?

Strong prospects in the Distribution Solutions segment is likely to boost McKesson's (MCK) top-line performance in the fiscal first quarter.

    Will Core Segmental Growth Aid Stryker (SYK) in Q2 Earnings?

    Stryker's (SYK) strong segmental performance and acquisition-driven strategy are likely to drive Q2 earnings.

      Should Value Investors Consider McKesson (MCK) Stock Now?

      Let's see if McKesson Corporation (MCK) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

        Sweta Jaiswal headshot

        Amazon Forays Into Pharmacy Business: Red Alert for Others?

        Amazon's entry into the high-potential pharmaceutical industry deals a blow to share prices of major players.

          McKesson (MCK) Issues Strong Preliminary Results for Q1

          McKesson Corporation (MCK) declares solid preliminary results for Q1, courtesy of deals, divestitures and acquisitions.

            Why Is McKesson (MCK) Up 1.7% Since Its Last Earnings Report?

            McKesson (MCK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

              McKesson's (MCK) Q4 Earnings Miss Estimates, Sales Improve Y/Y

              McKesson (MCK) witnesses strong growth in its Distribution Solutions segment in Q4 of fiscal 2018.

                Is McKesson Corporation (MCK) a Suitable Value Stock Now?

                Let's see if McKesson Corporation (MCK) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

                  Mark Vickery headshot

                  Top Stock Reports for Lockheed Martin, Mastercard & Colgate

                  Today's Research Daily features new research reports on 16 major stocks, including Lockheed Martin (LMT), Mastercard (MA) and Colgate (CL).

                    McKesson (MCK) Beats on Earnings and Sales in Q3

                    McKesson Corporation (MCK) delivers strong performance on the back of solid organic growth.

                      McKesson (MCK) Beats on Earnings and Sales in Q2

                      McKesson's adjusted earnings of $3.28 per share came above the Zacks Consensus Estimate of $2.78 and increased from $2.96 in the year-ago quarter.

                        Should You Buy McKesson Corporation (MCK) Ahead of Earnings?

                        McKesson (MCK) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

                          Mckesson (MCK) to Report Q2 Earnings: A Beat in the Cards?

                          McKesson Corporation (MCK) expects a strong second quarter owing to a gradually stabilizing generic and branded market.

                            Is McKesson (MCK) a Great Stock for Value Investors?

                            Let's see if McKesson Corporation (MCK) stock is a good choice for value-oriented investors right now from multiple angles.

                              AmerisourceBergen's PharMEDium Slows Down, Competition Rife

                              AmerisourceBergen Corporation (ABC) is facing immediate integration risks from its acquisition of PharMEDium. Also, competition in the generic space raise concern.

                                McKesson (MCK) Misses on Earnings and Sales in Q1

                                McKesson???s adjusted earnings of $2.46 per share missed the Zacks Consensus Estimate of $2.81 and decreased from $3.15 in the year-ago quarter.

                                  AmerisourceBergen's PharMEDium Slows Down, Competition Rife

                                  On Jul 10, we issued an updated research report on Chesterbrook, PA-based AmerisourceBergen Corporation (ABC).

                                    Should Value Investors Consider McKesson (MCK) Stock?

                                    Value investing is easily one of the most popular ways to find great stocks in any market environment.

                                      Why Is McKesson (MCK) Up 13% Since the Last Earnings Report?

                                      McKesson (MCK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                        McKesson (MCK) Up 7.5% Since Earnings Report: Can It Continue?

                                        McKesson (MCK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                          McKesson Corporation: Should Value Investors Pick this Stock?

                                          Value investing is easily one of the most popular ways to find great stocks in any market environment.

                                            McKesson (MCK) Beats on Earnings in Q3, Inks Buyout Deal

                                            McKesson Corporation (MCK) reported third-quarter fiscal 2017 earnings of $3.03 per share, beating the Zacks Consensus Estimate of $2.95 but declining from the year-ago figure of $3.18.

                                              McKesson (MCK) Q3 Earnings: Stock Likely to Disappoint?

                                              McKesson Corporation (MCK), one of the largest healthcare services providers, is scheduled to report third-quarter fiscal 2017 results on Jan 25.

                                                McKesson (MCK) to Pay $150 Million to Department of Justice

                                                McKesson (MCK) has finalized to resolve U.S. Drug Enforcement Administration and Department of Justice potential federal civil and administrative claims.

                                                  McKesson (MCK) Closes Rexall Health Acquisition in Canada

                                                  McKesson Corporation (MCK) announced that it has completed the acquisition of Canada-based Rexall Health for $2.1 billion